Allergan Plc (AGN): Adverse ruling on Restasis patent in US...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	829
Posts	119609
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 137

Monday, 10/16/2017 2:04:54 PM

Monday, October 16, 2017 2:04:54 PM

Adverse ruling on Restasis patent in US District Court:

https://finance.yahoo.com/news/u-district-court-eastern-district-174500864.html

Allergan plc…today acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid. The Company will appeal the Court's ruling.

…The patents include United States Patent Nos. 8,629,111; 8,648,048; 8,685,930 and 9,248,191. These patents, along with United States Patent Nos. 8,633,162 and 8,642,556, are listed in the Orange Book for RESTASIS and expire on August 27, 2024.

Unless overturned on appeal, the Districtt Court’s ruling blows up AGN’s patent settlement with PFE (#msg-135360904).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”